DEA Extends Medical Marijuana Registration to the Full Supply Chain

Medical marijuana manufacturers, growers, distributors, and testing labs have been navigating a federal compliance gap since the Trump administration’s rescheduling order took effect in late April. The Drug Enforcement Administration is now moving to close it: new registration forms for those business types are coming in the weeks ahead, the agency has announced — though the timeline cuts close against an expedited-processing window that expires in late June 2026.

A Dispensary-First Rollout

Acting Attorney General Todd Blanche signed the order placing state-licensed medical marijuana into Schedule III of the federal drug schedule on April 22, 2026. The order took effect on April 28, 2026, when it was published in the Federal Register — and on that date, federal registration requirements came into force for operators across the cannabis supply chain. The Justice Department’s announcement described a registration pathway designed to cover manufacturers, distributors, and dispensers alike. But the DEA released its first registration form for dispensaries only, leaving manufacturers, cultivators, analytical labs, and distributors without a form to file.

That gap is now formally acknowledged. According to a notice posted on DEA’s diversion registration portal, updated application forms are coming for four additional business types: medical marijuana manufacturers, bulk manufacturers (a category that covers growers and cultivators), analytical labs, and distributors. No exact launch date has been given.

The compressed timeline matters because the rescheduling order’s registration pathway includes a 60-day expedited window, running from the Federal Register publication date of April 28, 2026 through late June 2026. Operators who file within that window can continue operating under their existing state licenses while DEA reviews their federal applications — the agency committed to processing those early filings within six months. Applications filed after the window still qualify for registration, but without the same continuity protection or processing guarantee.

California has been moving faster than most states to help operators access the new federal pathway. The California Department of Cannabis Control updated its guidance to ease the transition for state licensees — as covered in our earlier reporting on the DCC’s license-switch guidance.

What Manufacturers Have to Prepare For

Registration paperwork aside, manufacturers face a compliance obligation that dispensaries do not: a federal purchase-and-resale mechanism written into the rescheduling order to satisfy U.S. treaty obligations.

Under the United Nations Single Convention on Narcotic Drugs — the international drug control treaty that requires a government agency to serve as the exclusive buyer of cannabis production — the order creates a paper transaction. Registered manufacturers must establish a nominal price for their crops. DEA then executes a purchase at that price and immediately resells those crops back to the manufacturer or a related entity at the same price plus an administrative fee. The manufacturer’s crops must remain in a DEA-accessible facility until the transaction is complete.

The mechanism is a compliance formality, but it carries real operational requirements: storage facilities that DEA can access on demand, documentation for the transaction record, and likely new internal procedures around crop-sale accounting. Growers and bulk manufacturers coming through the new forms will need to understand this requirement before they register.

For distributors and labs, the obligations are more conventional. Registrants must maintain inventory records aligned with federal standards, comply with federal security requirements, and meet labeling specifications. The order explicitly allows registrants to satisfy those federal security requirements by complying with their existing state security frameworks — a design choice that minimizes disruption for operators already in good standing under state programs. State-required records and forms are accepted for federal reporting “to the maximum extent permissible.”

The Broader Picture

The forms expansion is one piece of a larger buildout of federal registration infrastructure under the April 2026 order — which is not a full rescheduling of marijuana. State-licensed medical marijuana and FDA-approved marijuana drug products moved to Schedule III when the order took effect on April 28, 2026. Adult-use cannabis, synthetic THC, and unlicensed marijuana all remain Schedule I.

A separate, parallel proceeding is underway to evaluate broader rescheduling of marijuana — covering all forms, not just the medical and FDA-approved categories the order addressed. An administrative hearing on that question begins June 29, 2026. Interested parties seeking to participate had until May 24, 2026 to file notice of intention.

Closing the registration gap for the supply chain above the dispensary level is a meaningful step for the operators who have been in functional limbo since late April. The question those forms cannot answer — and that the June 29, 2026 hearing will begin to address — is where the operators of adult-use programs in more than two dozen states fit into a federal framework that still treats their products as Schedule I.